P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats

International Journal of Neuropsychopharmacology

Volumn 13, Issue 8, 2010, Pages 1067-1077

  Pacchioni, Alejandra M ^a   Gabriele, Amanda ^a   Donovan, Jennifer L ^a   Lindsay Devane, C ^a   See, Ronald E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine; p glycoprotein; PSC 833; risperidone; striatum

Indexed keywords

AMPHETAMINE; DOPAMINE; GLYCOPROTEIN P; RISPERIDONE; VALSPODAR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CATALEPSY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT;

ANIMALS; CATALEPSY; CORPUS STRIATUM; CYCLOSPORINS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE;

EID: 77957238019     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990782     Document Type: Article

References (35)

1. Atadja P, Watanabe T, Xu H, Cohen D (1998). PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer and Metastasis Reviews 17, 163-168. (Pubitemid 28391950)
2. Bauer B, Hartz AM, Fricker G, Miller DS (2005). Modulation of p-glycoprotein transport function at the blood-brain barrier. Experimental Biology and Medicine (Maywood) 230, 118-127.
3. Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002). In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences 71,163-169.
4. Commissiong JW (1985). Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochemical Pharmacology 34, 1127-1131. (Pubitemid 15009224)
5. Davis JM, Chen N (2004). Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 24, 192-208. (Pubitemid 38380844)
6. Ellenbroek B, Cools AR (1988). The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sciences 42, 1205-1213. (Pubitemid 18064273)
7. Farde L, Nordstrom AL, Wiesel FA, Pauli S, et al. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
8. Grimm JW, See RE (1998). Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone. Brain Research 801, 182-189.
9. Ichikawa J, Meltzer HY (2000). The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Research 858, 252-263. (Pubitemid 30119986)
10. Janssen PA, Niemegeers CJ, Schellekens KH (1965). Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? 'Neuroleptic activity spectra' for rats. Arzneimittel-Forschung 15, 104-117.
11. Johnson BM, Charman WN, Porter CJ (2003). Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metabolism and Disposition: The Biological Fate of Chemicals 31, 1151-1160.
12. Kirschbaum KM, Henken S, Hiemke C, Schmitt U (2008). Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behavioural Brain Research 188, 298-303.
13. Kruzich PJ, See RE (2000). An evaluation of the role of 5-HT(2) receptor antagonism during subchronic antipsychotic drug administration in rats. Brain Research 875, 35-43.
14. Leysen JE, Janssen PM, Gommeren W, Wynants J, et al. (1992). In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Molecular Pharmacology 41, 494-508.
15. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl. 1), 1-93. (Pubitemid 40677047)
16. Ogren SO (1996). The behavioural pharmacology of typical and atypical antipsychotic drugs. In: Cersnansky, JG (Ed.), Handbook of Experimental Pharmacology (pp. 225-266). Berlin: Springer.
17. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
18. Robinson TE, Whishaw IQ (1988). Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Research 450, 209-224.
19. Rodriguez M, Ortega I, Soengas I, Suarez E, et al. (2004). Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. Journal of Pharmacy and Pharmacology 56, 367-374. (Pubitemid 38380219)
20. Schinkel AH, Mayer U, Wagenaar E, Mol CA, et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences USA 94, 4028-4033. (Pubitemid 27180493)
21. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, et al. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502. (Pubitemid 24153990)
22. Schotte A, Janssen PF, Gommeren W, Luyten WH, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73. (Pubitemid 26112775)
23. See RE, Chapman MA (1994). The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Critical Reviews in Neurobiology 8, 85-124.
24. See RE, Lynch AM, Aravagiri M, Nemeroff CB, et al. (1995). Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Research 704, 202-209. (Pubitemid 26009941)
25. See RE, Sorg BA, Chapman MA, Kalivas PW (1991). In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists. Neuropharmacology 30, 1269-1274.
26. Shi X, McGinty JF (2007). Repeated amphetamine treatment increases phosphorylation of extracellular signal-regulated kinase, protein kinase B, and cyclase response element-binding protein in the rat striatum. Journal of Neurochemistry 103, 706-713. (Pubitemid 47498014)
27. Soares-da-Silva P, Garrett MC (1990). A kinetic study of the rate of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: implications for the origin of DOPAC. Neuropharmacology 29, 869-874. (Pubitemid 20347430)
28. Swerdlow NR, Geyer MA, Braff DL (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156,194-215.
29. Volonte M, Monferini E, Cerutti M, Fodritto F, et al. (1997). BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. Journal of Neurochemistry 69, 182-190. (Pubitemid 27274171)
30. Wang JS, Ruan Y, Taylor RM, Donovan JL, et al. (2004). The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. International Journal of Neuropsychopharmacology 7, 415-419. (Pubitemid 39648071)
31. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, et al. (2006). Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187, 415-423.
32. Zetterstrom T, Sharp T, Collin AK, Ungerstedt U (1988). In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC European Journal of Pharmacology 148, 327-334.
33. Zetterstrom T, Sharp T, Ungerstedt U (1984). Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. European Journal of Pharmacology 106, 27-37. (Pubitemid 15189023)
34. Zetterstrom T, Sharp T, Ungerstedt U (1986). Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. Naunyn-Schmiedebergs Archives of Pharmacology 334, 117-124. (Pubitemid 16000278)
35. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, et al. (2007). Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32, 757-764. (Pubitemid 46426181)